In conclusion, our study shows that ablative SBRT leads to transient lymphodepletion but a significant increase in the fraction of proliferating CD4+ and CD8+ circulating T-cells after treatment in lung metastatic disease, consistent with our findings in primary lung cancer. The gene discussed is CD8A; the disease is lung cancer.